(Bloomberg) -- Taking Stock with Kathleen Hays and Pimm Fox. \u0010 \u0010GUEST: \u0010Cynthia Koons \u0010Health Care Reporter \u0010Bloomberg Editorial \u0010on Pfizer beating out rivals to buy biopharmaceutical company, Medivation, and its blockbuster cancer drug for $14 billion.

<p>(Bloomberg) -- Taking Stock with Kathleen Hays and Pimm Fox. \u0010 \u0010GUEST: \u0010Cynthia Koons \u0010Health Care Reporter \u0010Bloomberg Editorial \u0010on Pfizer beating out rivals to buy biopharmaceutical company, Medivation, and its blockbuster cancer drug for $14 billion.</p>

Alix Steel and Paul Sweeney harness the power of Bloomberg Intelligence to analyze market news and provide in-depth company and industry research. Watch us LIVE on YouTube: http://bit.ly/3vTiACF.

<p>Alix Steel and Paul Sweeney harness the power of Bloomberg Intelligence to analyze market news and provide in-depth company and industry research. Watch us LIVE on YouTube: <a href="http://bit.ly/3vTiACF">http://bit.ly/3vTiACF</a>.</p>

Alix Steel and Paul Sweeney harness the power of Bloomberg Intelligence to analyze markets, companies and industries.

Bloomberg Intelligence

Koons on Pfizer Agreeing to Buy Medivation (Audio)

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/baf42b53-0921-4699-b44b-ae3c008f554d/transcript

Advertisement